Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de fase Ib de BKM120 con cisplatino y XRT en cáncer de células escamosas localmente avanzado de alto riesgo de cabeza y cuello

21 de octubre de 2026 actualizado por: Robert Haddad, MD, Dana-Farber Cancer Institute

Un estudio de fase Ib de BKM120 con cisplatino semanal y radioterapia en cáncer de células escamosas de cabeza y cuello localmente avanzado de alto riesgo

This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.

Descripción general del estudio

Descripción detallada

  • This phase Ib study is combining standard chemoradiotherapy with weekly cisplatin and BKM120 to assess tolerability of this combination in high risk patients with locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). The investigators will also obtain preliminary information about the efficacy of this treatment.
  • The participant will receive the study drug buparlisib once daily, by mouth, for 45 days. The participant will be given a study drug-dosing diary for each cycle. It will include special instructions for taking the study drug at home.
  • The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study before and how well they have tolerated their doses.
  • All participants will receive weekly cisplatin injection. Cisplatin will be given intra-venously (IV) on days: (1, 8, 15, 22, 29, 36 and 43) at DFCI.
  • All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks, delivered at DFCI. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor.
  • The investigators would like to keep track of the participant's medical condition. Follow-up will continue every 4 to 12 weeks after the end of treatment for the first year and at the investigator's discretion thereafter.

Tipo de estudio

Intervencionista

Inscripción (Actual)

23

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Dana-Farber Cancer Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent.
  • Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented SCC of the cervical lymph nodes, with unknown primaries.
  • >10 pack years of tobacco use
  • Age ≥ 18 years
  • ECOG performance status ≤ 2
  • At least one site of measurable disease
  • Adequate bone marrow function as shown by: ANC > 1.5 x 109/L, Platelets >100 x 109/L, Hb >9 g/dL
  • Total calcium (corrected for serum albumin) within normal limits
  • Magnesium ≥ the lower limit of normal
  • Potassium within normal limits for the institution.
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
  • Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
  • Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min
  • Serum amylase ≤ ULN
  • Serum lipase ≤ ULN
  • Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)
  • Signed informed consent
  • INR ≤ 2

Exclusion Criteria:

  • Distant metastatic disease
  • Less than or equal to 10 pack years of tobacco history
  • Received prior chemotherapy
  • Received prior radiation to the head and neck or adjacent anatomical site
  • Received prior treatment with a P13K inhibitor.
  • Known hypersensitivity to BKM120 or to its excipients
  • Acute or chronic liver, renal disease or pancreatitis
  • Mood disorders ≥ CTCAE grade 3
  • Diarrhea ≥ CTCAE grade 2
  • Active cardiac disease
  • History of cardiac dysfunction including any of the following:
  • Patient has poorly
  • Impairment of gastrointestinal (GI) function
  • Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.
  • Chronic treatment with steroids or another immunosuppressive agent.
  • Herbal medications and certain fruits within 7 days prior to starting study drug.
  • Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Appendix B for a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak inhibitors of CYP3A is allowed).
  • Undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  • Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant.
  • Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control.
  • Known diagnosis of human immunodeficiency virus (HIV) infection
  • History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dose Level 1
  • 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.
  • Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).
  • Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.

BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

Otros nombres:
  • Buparlisib

Cisplatin is a chemotherapy drug

Otros nombres:
  • Platinol
  • Platinol-AQ

IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells

Otros nombres:
  • IMRT
Experimental: Dose Level 2
  • 40 mg BKM120 will be administered orally daily for 45 days.
  • Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).
  • Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.

BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

Otros nombres:
  • Buparlisib

Cisplatin is a chemotherapy drug

Otros nombres:
  • Platinol
  • Platinol-AQ

IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells

Otros nombres:
  • IMRT

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Maximum Tolerated Dose of Cisplatin
Periodo de tiempo: While on treatment, up to 66 days

The trial uses 3+3 design to determine maximum tolerated dose (MTD).

While on treatment, up to 66 days
Maximum Tolerated Dose of BKM120
Periodo de tiempo: While on treatment, up to 66 days

The trial uses 3+3 design to determine maximum tolerated dose (MTD).

While on treatment, up to 66 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Best Overall Response
Periodo de tiempo: Measured at end of treatment, up to 66 days

The best overall response for each patient is given per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) criteria:

Complete Response (CR) - Disappearance of all target and non-target lesions and lymph node short axis is <10 mm and no new lesions

Partial Response (PR)

  • Disappearance of target lesions and >=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions or
  • >=30% decrease in sum of target lesion diameter and no new lesions

Stable Disease (SD)

- Less than 5 mm increase in target lesion diameter unless it results in a >=20% increase in diameter and >=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions

Progressive Disease (PD)

  • >20% increase in target lesion diameter, must be an absolute increase of 5mm or
  • Substantial worsening in non-target lesion or
  • New lesion present
Measured at end of treatment, up to 66 days
Median Time to Progression
Periodo de tiempo: Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)

The median amount of time from baseline to progression and/or death. Patients known to be alive at last contact are censored at last contact. All patients alive at 24 months from baseline are censored at 24 months.

Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
24 Month Overall Survival
Periodo de tiempo: Up to 24 months

The probability of survival at 24 months using Kaplan-Meier estimates. Patients alive at 2 years are censored at 2 years.

Up to 24 months
Median Anxiety Score Change
Periodo de tiempo: From baseline to cycle 9, up to 66 days.

The median change in score on the Generalized Anxiety Disorder - 7 (GAD-7) questionnaire from baseline to cycle 9.GAD-7 has 7 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 21. Higher score represents worse anxiety.

From baseline to cycle 9, up to 66 days.
Median Depression Score Change
Periodo de tiempo: From baseline to cycle 9, up to 66 days.

The median change in score on the Patient Health Questionnaire - 9 (PHQ-8) from baseline to cycle 9. PHQ-9 has 9 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 27. Higher score represents worse depression.

From baseline to cycle 9, up to 66 days.
P13K Status by Response
Periodo de tiempo: Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.

Phosphoinositide 3-kinase (PI3K) biomarker status, either positive or negative, analyzed using established methods from tumor biopsies. P13K status is reported by response, either responder (CR or PR) or non-responder (SD or PR).

Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Robert Haddad, MD, Brigham and Women's Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de septiembre de 2014

Finalización primaria (Actual)

6 de diciembre de 2019

Finalización del estudio (Actual)

1 de enero de 2022

Fechas de registro del estudio

Enviado por primera vez

1 de abril de 2014

Primero enviado que cumplió con los criterios de control de calidad

11 de abril de 2014

Publicado por primera vez (Estimado)

15 de abril de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de octubre de 2026

Última verificación

1 de noviembre de 2024

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir